Search

Your search keyword '"Kampmann, Peter"' showing total 168 results

Search Constraints

Start Over You searched for: Author "Kampmann, Peter" Remove constraint Author: "Kampmann, Peter"
168 results on '"Kampmann, Peter"'

Search Results

2. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

3. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

4. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

7. Intelligenter Antrieb

8. Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause.

9. A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia

11. Adaptive Control for Underwater Gripping Systems

12. Underwater Multi-modal Sensing for Environmental Mapping and Vehicle Navigation

13. Intelligent Propulsion

14. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

16. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

19. S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

22. Intelligent Propulsion

24. Temperature–Humidity-Dependent Wind Effects on Physiological Heat Strain of Moderately Exercising Individuals Reproduced by the Universal Thermal Climate Index (UTCI)

26. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

28. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

30. Tactile Sensors Based Object Recognition and 6D Pose Estimation

31. Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context

34. Prostatic artery embolization in men with severe hemophilia a:a case report of two patients

35. SARS-CoV-2 vaccine-induced immune thrombosis and thrombocytopenia

36. Work-up of thrombophilia

38. Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

39. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

40. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia

41. Histiocytic Sarcoma:Challenging Course, Dismal Outcome

42. SARS-CoV-2-vaccineinduceret immuntrombose og trombocytopeni

43. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

46. First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

47. Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis

48. AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years

49. Venøs tromboembolisk sygdom ved COVID-19

50. Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis : A Pre and Post-Intervention Analysis

Catalog

Books, media, physical & digital resources